Zhejiang Yatai Pharmaceutical 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Jianwei Cen

최고 경영자

CN¥507.6k

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	2.6yrs
이사회 평균 재임 기간	2.6yrs

최근 관리 업데이트

Recent updates

Subdued Growth No Barrier To Zhejiang Yatai Pharmaceutical Co., Ltd. (SZSE:002370) With Shares Advancing 27%

Aug 27

CEO

Jianwei Cen (52 yo)

less than a year

테뉴어

CN¥507,600

보상

Mr. Jianwei Cen is General Manager of Zhejiang Yatai Pharmaceutical Co. Ltd. from February 7, 2024. Mr. Cen was Deputy General Manager of Zhejiang Yatai Pharmaceutical Co. Ltd.from April 15, 2022 to Febru...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jianwei Cen	General Manager	less than a year	CN¥507.60k	데이터 없음
Jingyang Xu	Financial Director & Accounting Supervisor	2.6yrs	CN¥487.20k	데이터 없음
Wei Xu	Board Secretary	2.6yrs	CN¥487.40k	데이터 없음
Bao Kun Hu	Deputy General Manager	16.9yrs	CN¥404.00k	데이터 없음
Qin Shui Tan	Deputy General Manager	10.9yrs	CN¥453.60k	데이터 없음

2.6yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: 002370 의 관리팀은 경험 ( 2.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Min Tu	Supervisor	2.7yrs	데이터 없음	데이터 없음
Xiaoming Huang	Director	2.6yrs	CN¥1.04m	데이터 없음
Cai Fu	Vice Chairman of the Board	2.6yrs	데이터 없음	데이터 없음
Lingbo Song	Non-Independent Director	2.6yrs	데이터 없음	데이터 없음
Wei Huang	Non-Independent Director	2.6yrs	CN¥359.60k	데이터 없음
Yajian Zhou	Non-Independent Director	2.6yrs	CN¥306.20k	데이터 없음
Haizhou Lu	Independent Director	2.6yrs	CN¥100.00k	데이터 없음
Yuehui Liu	Independent Director	2.6yrs	CN¥100.00k	데이터 없음
Lingjie Song	Chairman	2.6yrs	데이터 없음	데이터 없음
Min Cai	Independent Director	2.6yrs	CN¥100.00k	데이터 없음
Huaying Zhou	Supervisor	2.6yrs	데이터 없음	데이터 없음

2.6yrs

평균 재임 기간

49yo

평균 연령

경험이 풍부한 이사회: 002370 의 이사회는 경험(평균 재직 기간 2.6 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Zhejiang Yatai Pharmaceutical 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Zhejiang Yatai Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

High number of new and inexperienced directors

Zhejiang Yatai Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2022

High number of new and inexperienced directors

Zhejiang Yatai Pharmaceutical Co., Ltd. Announces Executive Appointments

Recent updates

Third quarter 2024 earnings released: CN¥0.012 loss per share (vs CN¥0.028 loss in 3Q 2023)

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

New major risk - Share price stability

Ningbo Heyi Culture Media Co., Ltd agreed to acquire Shanghai Xingaofeng Newsummit Biopharma Co., Ltd. from Zhejiang Yatai Pharmaceutical Co., Ltd. (SZSE:002370) for CNY 1.4 million.

Subdued Growth No Barrier To Zhejiang Yatai Pharmaceutical Co., Ltd. (SZSE:002370) With Shares Advancing 27%

Second quarter 2024 earnings released: EPS: CN¥0.018 (vs CN¥0.049 in 2Q 2023)

New minor risk - Share price stability

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

Full year 2023 earnings released: CN¥0.02 loss per share (vs CN¥0.25 loss in FY 2022)

Zhejiang Yatai Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

New minor risk - Share price stability

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: CN¥0.028 loss per share (vs CN¥0.05 loss in 3Q 2022)

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 28, 2023

Second quarter 2023 earnings released: EPS: CN¥0.049 (vs CN¥0.05 loss in 2Q 2022)

Full year 2022 earnings released: CN¥0.25 loss per share (vs CN¥0.43 loss in FY 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.10 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.04 loss in 2Q 2021)

Zhejiang Yatai Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2022

First quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.04 loss in 1Q 2021)

High number of new and inexperienced directors

Zhejiang Yatai Pharmaceutical Co., Ltd. Announces Executive Appointments

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: CN¥0.10 loss per share (vs CN¥0.098 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.04 loss per share (vs CN¥0.05 loss in 2Q 2020)

First quarter 2021 earnings released: CN¥0.04 loss per share (vs CN¥0.05 loss in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.05 (vs CN¥3.86 loss in FY 2019)

Zhejiang Yatai Pharmaceutical Co., Ltd.(XSEC:002370) dropped from S&P Global BMI Index

New 90-day low: CN¥3.07

New 90-day low: CN¥3.62

New 90-day low: CN¥4.42

New 90-day low: CN¥4.77

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

Earnings released

New 90-day high - CN¥6.25

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령